Armistice Capital LLC Purchases 274,000 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Armistice Capital LLC boosted its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 33.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,098,000 shares of the company’s stock after acquiring an additional 274,000 shares during the period. Armistice Capital LLC’s holdings in Immunocore were worth $38,112,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Primecap Management Co. CA boosted its holdings in Immunocore by 5.5% in the fourth quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock valued at $137,517,000 after acquiring an additional 207,320 shares in the last quarter. Bellevue Group AG raised its position in shares of Immunocore by 14.5% in the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock worth $101,608,000 after purchasing an additional 354,973 shares during the last quarter. Millennium Management LLC raised its position in shares of Immunocore by 334.3% in the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after purchasing an additional 974,463 shares during the last quarter. Fiera Capital Corp raised its position in shares of Immunocore by 31.4% in the 4th quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock worth $36,266,000 after purchasing an additional 249,674 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its holdings in Immunocore by 15.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 383,558 shares of the company’s stock worth $13,313,000 after buying an additional 50,000 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

NASDAQ:IMCR opened at $28.55 on Thursday. The stock’s fifty day moving average is $29.45 and its 200 day moving average is $32.04. Immunocore Holdings PLC Sponsored ADR has a fifty-two week low of $27.56 and a fifty-two week high of $40.71. The firm has a market capitalization of $1.45 billion, a PE ratio of -51.91 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 EPS. On average, sell-side analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on IMCR. Zacks Research upgraded Immunocore from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Mizuho set a $38.00 price objective on Immunocore in a research note on Thursday, February 19th. Needham & Company LLC boosted their price target on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Immunocore has an average rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Company Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.